• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.94 -0.93 (-3.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals ↗
October 16, 2024
 
Via Benzinga
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
October 16, 2024
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
News headline image
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
October 16, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals ↗
September 13, 2024
 
Via Benzinga
News headline image
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know ↗
August 02, 2024
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 25, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday ↗
September 23, 2024
 
Via Benzinga
News headline image
What's Going With Apellis Pharmaceuticals Stock Friday? ↗
September 20, 2024
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
Via Benzinga
News headline image
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection ↗
September 20, 2024
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
Via Investor's Business Daily
News headline image
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
September 20, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights ↗
July 17, 2024
 
Via Benzinga
News headline image
What Analysts Are Saying About Apellis Pharmaceuticals Stock ↗
June 28, 2024
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 29, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 ↗
August 13, 2024
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some. 
Via InvestorPlace
News headline image
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases ↗
August 08, 2024
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
Via Benzinga
News headline image
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts ↗
May 28, 2024
 
Via Benzinga
News headline image
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals ↗
May 08, 2024
 
Via Benzinga
News headline image
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 08, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 01, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 09, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
June 28, 2024
 
Via Benzinga
News headline image
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 28, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 10, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 14, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap